An observational study in Glioma, sponsored by Tang-Du Hospital. Completed at 1 site in China. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Tang-Du Hospital · Observational
Accurately predicting the survival of pediatric glioma patients is crucial for informed clinical decision-making and selecting appropriate treatment strategies. However, there is a lack of prognostic models specifically tailored for pediatric glioma patients. This study aimed to address this gap by developing a time-dependent deep learning model to aid physicians in making more accurate prognostic assessments and treatment decisions.
This retrospective study focuses on survival prediction in pediatric glioma patients using a population-based approach. The model was trained using the Surveillance, Epidemiology, and End Results (SEER) Registry database. To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed between 2000 and 2018, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification. Only patients with available survival time were included, and those with unknown or missing clinical features were excluded. This cohort consisted of 258 pediatric glioma patients diagnosed at Tangdu Hospital in Xi\'an, China, between January 2010 and December 2018. These patients had complete clinical data and comprehensive follow-up records.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's enrollment of 9,532 is above the median of 88 across 238 observational studies indexed under Glioma.
Browse Glioma studies →Tang-Du Hospital is the lead sponsor of 164 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
the US Surveillance, Epidemiology, and End Results (SEER) between January 2000 and December 2018 and a Chinese registry (The Tangdu Hospital of the Fourth Military Medical Universitye) between January 2010 and December 2018
Exclusion Criteria:
The model was trained using the Surveillance, Epidemiology, and End Results (SEER) Registry database. To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed between 2000 and 2018, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification. Only patients with available survival time were included, and those with unknown or missing clinical features were excluded.
Other: Survival state
To assess the generalizability of the final model, an external validation cohort from China was used. This cohort consisted of 258 pediatric glioma patients diagnosed at Tangdu Hospital in Xi\'an, China, between January 2010 and December 2018. These patients had complete clinical data and comprehensive follow-up records.
Other: Survival state
We recorded clinically relevant information and survival status of pediatric glioma patients
overall survival
The primary outcome was overall survival (OS), which was defined as the time interval from the pediatric glioma diagnosis until death or the end of follow-up in SEER registry
Time frame: 2000.01-2018.12
overall survival
The primary outcome was overall survival (OS), which was defined as the time interval from the pediatric glioma diagnosis until death or the end of follow-up in Chinese registry
Time frame: 2010.01-2018.12
Plan to share: No — The data involves the relevant personal privacy information of the patient
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tang-Du Hospital